EDSA vs ADMA vs HALO vs GRFS vs JPM

For growth investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus 0. 2% for Grifols, S. A. (GRFS). Grifols, S. A. (GRFS) offers the better valuation at 11. 4x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Edesa Biotech, Inc. (EDSA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Grifols, S.

A. (GRFS) is the cheapest at 11. 4x versus Halozyme Therapeutics, Inc. at 27. 6x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 37x versus JPMorgan Chase & Co. 's 1. 08x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +357. 1%, compared to -86. 2% for Edesa Biotech, Inc. (EDSA). Over 10 years, the gap is even starker: HALO returned +701. 6% versus EDSA's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Edesa Biotech, Inc.

(EDSA) is the lower-risk stock at -0. 18β versus ADMA Biologics, Inc. 's 1. 11β — meaning ADMA is approximately -723% more volatile than EDSA relative to the S&P 500. On balance sheet safety, ADMA Biologics, Inc. (ADMA) carries a lower debt/equity ratio of 17% versus 44% for Halozyme Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Halozyme Therapeutics, Inc.

(HALO) is pulling ahead at 37. 6% versus 0. 2% for Grifols, S. A. (GRFS). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus 0. 0% for Edesa Biotech, Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for EDSA. At the gross margin level — before operating expenses — HALO leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 37x versus JPMorgan Chase & Co. 's 1. 08x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 6x forward P/E versus 14. 1x for JPMorgan Chase & Co. — 5. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADMA: 152. 4% to $21. 00.

In this comparison, GRFS (2.

8% yield), JPM (1. 9% yield) pay a dividend. EDSA, ADMA, HALO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Edesa Biotech, Inc.

(EDSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 18)). Both have compounded well over 10 years (EDSA: -99. 3%, ADMA: +15. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EDSA (Healthcare) and ADMA (Healthcare) and HALO (Healthcare) and GRFS (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EDSA is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock; HALO is a small-cap high-growth stock; GRFS is a small-cap deep-value stock; JPM is a large-cap deep-value stock. GRFS, JPM pay a dividend while EDSA, ADMA, HALO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.